Eli Lilly Approaches $1 Trillion Market Cap Driven by Weight Loss Drugs
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
- Market Cap Milestone: Eli Lilly briefly reached a $1 trillion market cap in November before retreating to approximately $960 billion, reflecting strong performance and investor interest in the pharmaceutical sector.
- Revenue Surge: The company generated over $10 billion in revenue last quarter from its weight loss drugs Zepbound and Mounjaro, driving a 54% increase in overall revenue, showcasing robust market demand for its product portfolio.
- Market Potential: Analysts project the weight loss market to approach nearly $100 billion by 2030, with Lilly's leadership and new drug developments poised to provide significant revenue growth opportunities in the future.
- Competitive Edge: Lilly's Zepbound demonstrated superior efficacy compared to Novo Nordisk's Wegovy in head-to-head trials, and its new oral candidate could become the only option without dietary restrictions, further solidifying its market position.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1078 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1064.040
Low
800.00
Averages
1078
High
1300
Current: 1064.040
Low
800.00
Averages
1078
High
1300
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
